Evaluation of Posaconazole Serum Concentrations Achieved With Delayed-release Tablets and Oral Suspension in Patients Undergoing Intensive Chemotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Leonora Muehlberg; Thomas Pabst; Carlo Largiadèr; Yolanda Aebi; Michael Hayoz; Konrad Muehlethaler; Stefan Zimmerli; Cédric Hirzel

doi:10.1093/ofid/ofae263

Evaluation of Posaconazole Serum Concentrations Achieved With Delayed-release Tablets and Oral Suspension in Patients Undergoing Intensive Chemotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Open Forum Infect Dis. 2024 May 6;11(5):ofae263. doi: 10.1093/ofid/ofae263. eCollection 2024 May.

Authors

Leonora Muehlberg¹, Thomas Pabst², Carlo Largiadèr³, Yolanda Aebi³, Michael Hayoz³, Konrad Muehlethaler⁴, Stefan Zimmerli¹, Cédric Hirzel¹

Affiliations

¹ Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
² Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland.
³ Department of Clinical Chemistry, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
⁴ Department of Clinical Microbiology, Institute for Infectious Diseases, University of Bern, Bern, Switzerland.

Abstract

Data on posaconazole serum levels of patients on prophylaxis with delayed-release tablets or oral suspension during intensive chemotherapy for acute myeloid leukemia and myelodysplastic syndrome are scarce. In this analysis, the proportion of patients with acute myeloid leukemia/myelodysplastic syndrome achieving posaconazole target concentrations with delayed-release tablets was higher than with oral suspension.

Keywords: acute myeloid leukemia; intensive chemotherapy; myelodysplastic syndrome; posaconazole prophylaxis.